- Trials with a EudraCT protocol (288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
288 result(s) found for: SARS coronavirus.
Displaying page 10 of 15.
EudraCT Number: 2017-001225-41 | Sponsor Protocol Number: M14-430 | Start Date*: 2018-04-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Comp... | |||||||||||||
Medical condition: Crohn's Disease (CD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) DE (Trial now transitioned) SE (Trial now transitioned) LV (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) IE (Completed) LT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) BG (Completed) BE (Trial now transitioned) SI (Completed) HR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001363-85 | Sponsor Protocol Number: 60152610 | Start Date*: 2020-04-23 | ||||||||||||||||
Sponsor Name:Odense University Hospital | ||||||||||||||||||
Full Title: COVID-19 Prophylaxis with hydroxychloroquine, Vitamin D, and Zinc supplementation in Danish nursing home residents – a randomized controlled trial | ||||||||||||||||||
Medical condition: Healthy volunteer (Prophylaxis for COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001994-66 | Sponsor Protocol Number: ECIT-PRO19 | Start Date*: 2020-05-06 |
Sponsor Name:Fundació Assistencial Mútua Terrassa | ||
Full Title: Ramdomised clinical trial of ivermectin for treatment and prophylaxis of COVID-19 | ||
Medical condition: SARS COVID-19 | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000365-33 | Sponsor Protocol Number: CHDR2043 | Start Date*: 2021-03-17 | |||||||||||
Sponsor Name:Molecular Partners AG | |||||||||||||
Full Title: A Phase 2a open label, non-comparative, single dose escalation study to evaluate the dynamics of viral clearance, pharmacokinetics and tolerability of ensovibep in patients with symptomatic COVID-1... | |||||||||||||
Medical condition: SARS-CoV-2 infection (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002120-37 | Sponsor Protocol Number: RESP301-002 | Start Date*: 2020-06-16 | |||||||||||
Sponsor Name:Thirty Respiratory Limited | |||||||||||||
Full Title: An open-label, adaptive randomized, controlled multicenter study to evaluate the efficacy and safety of RESP301 plus standard of care (SOC) compared to SOC alone in hospitalized participants with C... | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001765-37 | Sponsor Protocol Number: PROTOCOLO/ICO/COVID20 | Start Date*: 2020-04-11 | ||||||||||||||||
Sponsor Name:Institut Català d’Oncologia | ||||||||||||||||||
Full Title: Pragmatic clinical trial to evaluate the efficacy of hydroxychloroquine in the treatment of COVID-19 infection in two cohorts: patients with oncohaematological disease and SARS-CoV-2 positive witho... | ||||||||||||||||||
Medical condition: SAR COV2 virus infection, without radiological affectation. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-001958-36 | Sponsor Protocol Number: SDX_01 | Start Date*: 2022-08-29 |
Sponsor Name:Corporativo de Servicios Médicos Especializados S.A de C.V V (Centro Médico del Noroeste) | ||
Full Title: Endothelial protection in convalecent COVID-19 patients. The effect of Sulodexide on serum levels of biomarkers for endothelial dysfunction. A prospective, randomized, placebo-controlled, investiga... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by coronavirus 2 (SARS-CoV-2) and, thus, being a novel cause of sepsis and the the poor outcome of patients with sepsis was relat... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002871-36 | Sponsor Protocol Number: VIR-7831-5001 | Start Date*: 2020-11-27 | ||||||||||||||||
Sponsor Name:Vir Biotechnology, Inc. | ||||||||||||||||||
Full Title: A randomized, multi-center, double-blind, placebo-controlled study to assess the safety and efficacy of monoclonal antibody VIR-7831 for the early treatment of coronavirus disease 2019 (COVID-19) i... | ||||||||||||||||||
Medical condition: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the cause of coronavirus disease 2019 (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002293-28 | Sponsor Protocol Number: 2020-002293-28 | Start Date*: 2020-05-29 | |||||||||||
Sponsor Name:Karolinska University Hospital | |||||||||||||
Full Title: Resolving inflammatory storm in COVID-19 patients by Omega-3 polyunsaturated fatty acids. - A single-blind, randomized, placebo-controlled feasibility study | |||||||||||||
Medical condition: SARS-COV-2 Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001808-42 | Sponsor Protocol Number: PHM-2020-001 | Start Date*: 2020-06-17 | |||||||||||
Sponsor Name:Pharmamel S.L. | |||||||||||||
Full Title: PHASE II CLINICAL TRIAL, SINGLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED TO EXPLORE THE EFFECTIVENESS AND SAFETY OF MELATONIN I.V. IN PATIENTS WITH COVID-19 ENTERED INTO THE ICU (MELCOVID STUDY) | |||||||||||||
Medical condition: COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002857-28 | Sponsor Protocol Number: C4671002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI... | |||||||||||||
Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) BG (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001717-20 | Sponsor Protocol Number: COVIDIOL | Start Date*: 2020-04-20 | ||||||||||||||||
Sponsor Name:Fundación para la Investigación Biomédica de Córdoba | ||||||||||||||||||
Full Title: Prevention and treatment with Calcifediol of Coronavirus COVID-19-induced acute respiratory syndrome (SARS) | ||||||||||||||||||
Medical condition: Severe Acute Respiratory Syndrome in subjects with COVID-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002299-11 | Sponsor Protocol Number: SD-COVID19-01 | Start Date*: 2020-09-17 | |||||||||||
Sponsor Name:SigmaDrugs Research Ltd. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, adaptive-design study to assess the safety and efficacy of daily 200 mg fluvoxamine as add-on therapy to standard of care in moderate severity COVID-... | |||||||||||||
Medical condition: SARS-CoV-2 infected patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002869-34 | Sponsor Protocol Number: AT-03A-001 | Start Date*: 2020-08-11 | |||||||||||
Sponsor Name:Atea Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AT-527 in Subjects with Moderate COVID-19 | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002295-13 | Sponsor Protocol Number: APHP200552 | Start Date*: 2020-10-15 | |||||||||||
Sponsor Name:Assistance Publique - Hôpitaux Paris | |||||||||||||
Full Title: Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of conc... | |||||||||||||
Medical condition: The study population will consist of adults (18-80 years old) hospitalised for ≤48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test posit... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001953-36 | Sponsor Protocol Number: GC2005 | Start Date*: 2020-05-08 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A | ||||||||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of Prolastin® plus Standard Medical Treatment (SMT) versus SMT alone in Hospitalized Subjects w... | ||||||||||||||||||
Medical condition: Patients with Coronavirus Disease (COVID-19) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-001747-21 | Sponsor Protocol Number: ISPUP2020CT1 | Start Date*: 2020-07-06 | |||||||||||
Sponsor Name:Instituto de Saúde Pública Universidade Porto | |||||||||||||
Full Title: Impact of Montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): an investigator-initiated open labelled randomized controlled pragmatic trial | |||||||||||||
Medical condition: Novel coronavirus pneumonia (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003510-12 | Sponsor Protocol Number: GS-US-540-9012 | Start Date*: 2020-10-02 | |||||||||||
Sponsor Name:Gilead Sciences, Inc | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001673-75 | Sponsor Protocol Number: ABX464-401 | Start Date*: 2020-05-06 |
Sponsor Name:ABIVAX | ||
Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu... | ||
Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-001528-32 | Sponsor Protocol Number: ARCO-Homestudy | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Adaptive Randomized trial for therapy of COrona virus disease 2019 at home with oral antivirals | |||||||||||||
Medical condition: Coronavirus Covid 19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
